AKT1/protein kinase Ba is a protein-serine/threonine kinase that regulates multiple targets involved in cell survival and cell cycle progression in a variety of cell types including breast cancer cells. To explore the role of Akt1 in mammary gland function and tumorigenesis, transgenic mice were generated that express human AKT1 under the control of the MMTV promoter. Virgin transgenic mice did not exhibit a dominant phenotype, but upon cessation of lactation, a notable delay in involution occurred compared to age-matched nontransgenic mice. The delay in involution coincided with increased hyperplasia as evidenced by an increased number of binucleated epithelial cells and a marked elevation in cyclin D1 expression in mammary epithelium. The delayed involution phenotype corresponded to increased phosphorylation of Thr308 in AKT1 and Ser136 in BAD, but not phosphorylation of Ser21 in GSK-3a. There was no evidence of mammary dysplasia or neoplasia during the lifespan of multiparous transgenic mice. These data suggest that AKT1 is involved in cell survival in the lactating and involuting mammary gland, but that overexpression of AKT1 alone is insucient to induce transformation.
Introduction
The protein-serine/threonine kinase, Akt/protein kinase B, is the cellular homolog of the viral oncogene v-akt that was rescued from the AKT8 retrovirus infecting AKR mice (Staal, 1987) . Akt is activated following receptor tyrosine kinase activation by several growth factors including epidermal growth factor (EGF) (Okano et al., 2000; Wang et al., 2000) , heregulin (Olayioye et al., 2000) , hepatocyte growth factor (Bowers et al., 2000) , vascular endothelial growth factor (Gille et al., 2000) , insulin and insulin-like growth factor (IGF-1) (Alessi et al., 1996) , interleukins (Ahmed et al., 1997; del Peso et al., 1997) and nerve growth factor (Andjelkovic et al., 1998) . Akt activation occurs upon its recruitment to the plasma membrane via its pleckstrin homology domain and phosphorylation of Thr308 and Ser473 by PDK1 and a postulated secondary protein kinase, respectively (Cohen et al., 1997; Toker and Newton, 2000) .
Activation of Akt leads to the modulation of several proteins involved in apoptosis and cell cycle regulation through either transcriptional or posttranslational mechanisms. Phosphorylation of CREB by Akt leads to increased transcription of the cytoprotective protein Bcl-2 (Pugazhenthi et al., 2000) . The Forkhead family of transcription factors, including FKHR, FKHRL1 and AFX are phosphorylated by Akt, which results in their association with 14-3-3 proteins to prevent their translocation to the nucleus and activation of Fas ligand transcription (del Peso et al., 1999) . The pro-apoptotic Bcl-2 family member, BAD, is serially phosphorylated at Ser136 and Ser155 by Akt, which also leads to its association with 14-3-3 proteins, thereby preventing its association with and inactivation of the antiapoptotic proteins Bcl-2 and Bcl-X L (Datta et al., 2000) . Akt phosphorylation of IkB kinase leads to its activation and phosphorylation of IkB targeting IkB for, proteasomal degradation and leading to induction of NF-kBdependent transcription (Romashkova and Makarov, 1999) . Glycogen synthase kinase-3 (GSK-3) has also been identi®ed as a target of Akt, where phosphorylation of Ser9 inhibits its activity (Cross et al., 1995) and reduces proteasomal degradation of cyclin D (Diehl et al., 1998) . Akt can also enhance translation of cyclin D mRNA by an unknown mechanism (Muise-Helmericks et al., 1998) . Increased cyclin D levels lead to increased cell division by maintaining the retinoblastoma protein (RB) in a hyperphosphorylated, inactivated state (Muller and Helin, 2000; Pavletich, 1999) .
Of the three Akt isoforms, AKT1 and AKT2 overexpression have been linked to breast cancer. AKT2 was ampli®ed in approximately 12% of ovarian cancers and 3% of breast cancers and was associated with a poor prognosis (Bellacosa et al., 1995) . AKT1 levels were elevated in virtually all breast cancer cell lines, and its activity was stimulated by IGF-1, estradiol and heregulin (Ahmad et al., 1999; Altiok et al., 1999; Gibson et al., 1999; Liu et al., 1999) , resulting in resistance to apoptosis induced by TNFa, Fas ligand or wortmannin (Ahmad et al., 1999; Gibson et al., 1999; Zhou et al., 2000) .
To examine the role of Akt1 in the etiology of mammary tumorigenesis, transgenic mice were generated that express human AKT1 under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR). In this study, we demonstrate for the ®rst time that AKT1 expression during lactation results in a pronounced delay in involution, which was associated with hyperplasia and marked elevation of cyclin D1. Although MMTV-AKT1 mice did not exhibit mammary dysplasia or neoplasia in multiparous mice, our data suggest that Akt1 is an important survival factor in mammary epithelial cells during lactation and involution.
Results
Four transgenic founder lines 6, 19, 23 and 44, were produced, which express AKT1 under the control of the MMTV LTR. Mice were screened by PCR analysis with primers designed to detect a 446 bp fragment unique to the AKT1 transgene ( Figure 1a) . DNA from mice testing positive for AKT1 by PCR analysis was then assessed by Southern analysis where founder 23 expressed the highest copy number followed by founders 6 and 44 (Figure 1b) .
Expression of AKT1 was also determined using Western blotting (Figure 2a ). Akt1 was overexpressed in the mammary glands of virgin mice in founder lines 44 and 6, but not in founder line 23. Although commercially available AKT1 antibodies proved unsuitable for immunohistochemistry, activated AKT1 could be detected using an anti-phosphoThr308 AKT1 antibody (Figure 2b ). Expression of activated Akt1 was low but detectable in the mammary epithelium in the glands of all virgin mice with expression greatest in founder lines 44 and 6.
Whole mounts of mammary glands from founder lines 6 and 44 revealed dierences in ductal growth compared to their wild-type littermates (Figure 3a) . Little dierence in mammary gland morphology was evident in founder 6, whereas founder line 44 showed increased tubule branching. Multiparous mice from founder line 6 displayed marked tubule dilation and increased end-bud density compared to wild-type littermates (Figure 3b ). (6, 44, or 23) was digested with EcoRI, separated in a 1% agarose gel and subjected to Southern analysis using an AKT1 probe Transgene expression under the control of the MMTV LTR is strongly induced during pregnancy (Krane and Leder, 1996) . Since Akt is involved in multiple cell survival pathways that are relevant to mammary epithelium (Dufourny et al., 1997 (Dufourny et al., , 2000 Jackson et al., 2000; Lu et al., 1999; Zhou et al., 2000) , the eect of AKT1 overexpression in mammary epithelium during involution was examined. Female transgenic and non-transgenic littermates from founders 6 and 44, ranging in age from 16 ± 22 weeks, were bred and allowed to nurse their pups. Involution was induced in individual glands by teat sealing at days 10, 3 and 1 before weaning (Li et al., 1997) . In all instances, pups were weaned 18 days after birth and the glands harvested. Sealing had no overt eect on the ability of the pups to suckle or on their overall health, and had no eect on neighboring glands. Notable dierences in gland histology between transgenic and wild-type mice during involution were observed ( Figure  4 ). In wild-type mice (Figure 4c ,f,i,l), obvious signs of involution were seen at day 3 when the gland became engorged with milk, the acinar structure collapsed and signi®cant loss of epithelial cells occurred. By day 10, the gland had returned to a more normal, ductal structure, resembling the virgin gland. In founder line 6, the gland underwent apoptosis at approximately the same rate as the wild-type mouse ( Figure 4b ,e,h,k), but remained hyperplastic at day 10 of involution. Many regions within the gland had still not receded, and ducts still secreted milk as seen by the eosin-stained protein within the ductal lumina. A more severe phenotype was noted in founder line 44, where the mammary gland did not show any sign of involution at day 10 ( Figure 4a ,d,g,j) . Accompanying the delay in involution was the appearance of many binucleated epithelial cells and an increase in granulocytic cells within the lumina ( Figure 5 ), and was observed in both founder lines.
Expression of activated AKT1 was determined by immunohistochemistry using an antibody to phosphorylated Thr308 in AKT1. There was no evidence of staining at any stage of lactation and involution in the wild-type gland ( Figure 6 ). However, in the glands of transgenic mice, strong expression of activated AKT1 could be seen in the glands of lactating mice and at day 1 and day 10 of involution.
Since there was histological evidence of hyperplasia in all founder lines following lactation, and AKT1 has been shown to increase cyclin D levels (Diehl et al., 1998; Muise-Helmericks et al., 1998) , mammary glands were analysed immunohistochemically for cyclin D1 expression (Figure 7) . In all mice, cyclin D1 staining was evident during lactation on day 0. On day 1 of involution, cyclin D1 expression was absent in the mammary gland from wild-type mice, but was strongly expressed in all transgenic founder lines. By day 10 of involution, cyclin D1 levels remained high in all transgenic lines, even when almost fully involuted, but remained below detection in wild-type mice.
Western blotting was used to examine the phosphorylation of potential downstream targets of AKT1 and markers of involution in founder line 6 following lactation and involution (Figure 8 ). While levels of AKT1 did not dier between transgenic and wild-type mice, phosphorylation of Thr308 in AKT1 was elevated in transgenic mice and corresponded to the onset of involution. The increase in phospho-Thr308 AKT1 also corresponded to Ser136-BAD phosphorylation in transgenic mice during lactation and day 3 of involution. Phosphorylation of Ser21 in GSK-3a was also evident during lactation and day 3 of involution in both wild-type and transgenic mice and did not correlate with delayed involution. Phosphorylation of Tyr705 in STAT3, a marker of involution, was apparent in both wild-type and transgenic mice, but parsisted lougorin transgenic mice.
Discussion
The present study was designed to determine if mammary gland-directed expression of AKT1 would result in proliferative, dysplastic or neoplastic changes or alterations in tissue remodeling during mammary gland development. MMTV-AKT1 mice universally exhibited varying degrees of delayed involution, which coincided with elevated cyclin D1 levels, increased AKT1 activation and an increased number of mitotic cells (Figures 5 and 7) . The delay in involution correlated with the persistence of phospho-Tyr705-STAT3, which disappeared upon involution (Li et al., 1997; Chapman et al., 1999) . There was a direct correlation between prolonged expression of activated AKT and cyclin D1 in the involuting mammary gland of both founder lines (Figures 6 and 7) . While AKT activation was only moderately increased during lactation in wild-type mice (Figures 6 and 7) , continued AKT activation in transgenic mice appeared to maintain a pool of cyclin D1 that prevented involution. These results are consistent with the elevation of cyclin D1 by AKT through both translational (MuiseHelmericks et al., 1998) and post-translational mechanisms (Diehl et al., 1998) . Although inhibition of GSK-3 phosphorylation by AKT1 has been reported to increase cyclin D1 levels (Diehl et al., 1998) , both wild-type and transgenic mice exhibited a strong increase in GSK-3a phosphorylation during the early stages of involution. Since cyclin D1-dependent activa- tion of CDK4 plays a key role in the inactivation of RB to permit G1-S transit through the cell cycle (Pavletich, 1999) , increased cyclin D1 levels suggest an important mechanism for regulating mammary gland involution. Previous studies have shown that MMTVregulated expression of cyclin D1 in transgenic mice leads to mammary oncogenesis (Wang et al., 1994) , and that cyclin D1 acts in a cooperative manner with the molecular chaperone CDC37 to accelerate mammary tumor formation (Stepanova et al., 2000) . MMTV-Cdc25B mice also exhibited elevated cyclin D1 levels, delayed involution and hyperplasia , which was similar to the phenotype observed in MMTV-AKT1 mice. These studies all appear to provide a causal link between prolonged AKT activity, inappropriate cyclin D1 expression and delayed involution. It is interesting that the phenotype observed in MMTV-AKT1 mice is similar in some respects to that observed in transgenic mice expressing the TGFa transgene. Metallothionein (MT)-TGFa mice exhibited up to a six week delay in involution and the gland contained many binucleated cells showing hyperplasia (Smith et al., 1995) . TGFa activates the same pathway as EGF (Beerli and Hynes, 1996) , which through activation of erbB1 results in phosphoinositide 3-kinase (PI3-K) and AKT activation (Okano et al., 2000; Wang et al., 2000) , suggesting a possible point of convergence for the ErbB1 and the AKT signaling pathways in the mammary gland. Another potential point of convergence is the regulation of cyclin D as shown by the elevated cyclin D1 levels in the mammary gland of WAP-TGFa mice (Sandgren et al., 1995) . However, unlike TGFa transgenic mice, AKT1 mice or mice expressing constitutively active forms of AKT1 (Hutchinson et al., 2001; Schwertfeger et al., 2001) did not exhibit neoplasia. This suggests that targets downstream to TGFa other than AKT1 contribute to the malignant process and that activation of at least one additional signaling pathway is required for oncogenesis to occur.
AKT1 overexpression has been shown in numerous studies to prevent apoptosis induced by serum-or cytokine-deprivation (for review see Datta et al. (1999) ). Overexpression of AKT1 would therefore, be expected to tip the balance from apoptosis to survival. The appearance of phospho-Ser136 BAD in the mammary gland at lactation and at day 3 of Figure 4 Mammary gland morphology following lactation and involution. Mammary glands from founder lines 44 (a,d,g,j) and 6 (b,e,h,k) and wild-type (c,f,i,l) mice were obtained during lactation at day 0 (a ± c) and on day 1 (e ± f), day 3 (g ± i) and day 10 (j,l) after induced involution as described under Materials and methods. H & E staining. Magni®cation 1006 AKT1 expression in the mammary gland S Ackler et al involution in transgenic mice also suggests such a mechanism. Phosphorylation of BAD leads to its sequestration in the cytoplasm by 14-3-3 proteins (Datta et al., 2000) , preventing its translocation to the mitochondria and subsequent inhibition of apoptosis (Datta et al., 1997) . Thus, in addition to enhanced proliferation induced by elevated cyclin D1, BAD phosphorylation, at least early in involution, may contribute to the delay in involution resulting from AKT1 activation.
In conclusion, mammary gland-directed expression of AKT1 resulted in delayed involution associated with enhanced cyclin D1 expression and BAD phosphorylation. The delayed involution phenotype was neither associated with mammary tumor formation nor sustained hyperplasia. It appears therefore, that AKT1 overexpression alone is insucient for driving the tumorigenic process in mammary epithelial cells and that one or more additional signaling pathways are required.
Materials and methods

Generation of transgenic mice
MMTV-AKT1 was prepared by insertion of a 1.8 kb EcoRI fragment of the human AKT1 cDNA (Ahmad et al., 1999) into the EcoRI site in the plasmid MMTV-SV40-Bssk (kindly provided by Dr Philip Leder). This construct was then digested with SalI and SpeI, and the fragment containing the MMTV promoter, AKT1 sequences and SV40 poly-adenylation signal was isolated by electrophoresis in a 0.8% agarose gel and puri®ed using QIAquick TM (Qiagen). The plasmid was adjusted to a concentration of 2 mg/ml in 10 mM Tris pH 7.5, 0.1 mM EDTA (TE buer), and injected into the male pronucleus of FVB mouse embryos using standard techniques by the Transgenic Shared Resource, Lombardi Cancer Center. Four independent founders were generated and designated founder lines 6, 19, 23, and 44.
Southern analysis
DNA was extracted from 25 mg liver from transgenic and non-transgenic mice using DNeasy TM (Qiagen). Approximately 8 ± 10 mg of DNA was digested with EcoRI overnight and precipitated with ethanol at ± 808C. DNA was dissolved in 50 ml TE buer and separated in a 1% agarose gel. Following Southern blot transfer (Southern, 1975) onto Immobilon TM -Ny+ membranes (Millipore), DNA was hybridized with a human AKT1 cDNA probe labeled with biotinylated dCTP (Detector Random Primer DNA biotinylation kit, Kirkegaard & Perry Laboratories) and visualized with DNAdetector TM (Kirkegaard & Perry Laboratories) using CDP-Star as a substrate.
PCR analysis
DNA was extracted from mouse tail snips using DNeasy TM (Qiagen), and 200 ng DNA was used in each PCR reaction. The primers were designed to dierentiate between the AKT1 transgene and endogenous akt1. For AKT1, the forward primer (nt 477 ± 500), 5'-TGAGGAGCGGGAGGAGTGGACAAC-3', and the reverse primer (nt 900 ± 922), 5'-CCCGGGA-CAGGTGGAAGAACAGC-3', yielded a 446 bp fragment. DNA from a transgenic mouse, which tested positive by Southern blot analysis, was used as a positive control in all experiments. PCR was performed using a Biometra Thermocycler under the following conditions: denaturation at 958C for 1 min, annealing at 608C for 1 min and elongation at 728C for 1 min for 30 cycles. Samples were separated in a 1% agarose gel.
Whole mounts
Non-pregnant female mice were euthanized using CO 2 and cervical dislocation, and mammary glands were harvested, placed on dry, silanized glass slides and ®xed overnight in 1 part glacial acetic acid : 3 parts 100% ethanol. Tissues were rehydrated through successive incubations with 70% ethanol followed by distilled water, and stained with Carmine Red alum overnight. Tissues were then dehydrated through successive incubations in graded ethanol followed by mixed xylenes and mounted in Permount 1 (Fisher Scienti®c).
Involution studies
Mammary glands were harvested at days 0, 1, 3 and 10 following induced involution using the sealing procedure of Li et al (1997) . Involution was induced by painting the #4 Figure 5 Binucleated cells in the mammary gland undergoing involution. Binucleated cells (arrow) were present in the mammary gland from founder line 44 (`44 Trans'), but not in the mammary gland from wild-type mice (`Wild-type') at day 10 after inducing involution as described under Materials and methods. Magni®ca-tion 1006 Figure 6 Phospho-Thr308-AKT1 expression in the mammary gland following lactation and involution. Mammary glands from founder lines 44 and 6 as well as wild-type mice were stained immunohistochemically for phospho-Thr308-AKT1. Tissue was obtained from the lactating mammary gland on day 0, day 1 and day 10 after inducing involution as described under Materials and methods. Magni®cation 1006 Figure 7 Cyclin D1 expression in the mammary gland following lactation and involution. Mammary glands from founder lines 44 (a,d,g) and 6 (b,e,h) as well as wild-type (c,f,i) mice were stained immunohistochemically for cyclin D1. Tissue was obtained from the lactating mammary gland on day 0 (a ± c), day 1 (d ± f) and day 10 (g ± i) after inducing involution as described under Materials and methods. Magni®cation 1006 AKT1 expression in the mammary gland S Ackler et al (day 10), #9 (day 3) and #3 (day 1) teats with acrylate at days 10, 3 and 1, respectively, prior to weaning. Mammary gland #8 was used as the non-involuting control (day 0). On the day of weaning, nursing females were sacri®ced as described above, and the #3, #4, #8 and #9 glands were excised. Half of each gland was snap frozen in liquid nitrogen for protein extraction and immunoblot analysis, and the other half was stored in formalin overnight for further processing for histopathology and immunohistochemistry.
Histopathology and immunohistochemistry
Formalin-®xed mammary glands from virgin and lactating mice were embedded in paran by the Histopathology and Tissue Core Facility, Lombardi Cancer Center. Tissue sections were stained with either hematoxylin and eosin (H & E) for histopathology or with hematoxylin alone for nuclear staining. For immunostaining, slides were deparanized with xylenes, and rehydrated in graded alcohols. Slides were treated in 0.1% trypsin/phosphate-buered saline (PBS) at 378C for 30 min, followed by a 10 min rinse under running deionized water. Endogenous peroxidases were quenched with 0.3% H 2 O 2 in methanol for 30 min. Blocking solution consisted of 2% rabbit or goat serum (depending on source of secondary antibody), 5% BSA in PBS, and was applied for 1 h. Primary and secondary antibodies were applied for 1 h each in blocking solution. ABC reagent coupled to peroxidase (#PK-6001, Vector Laboratories) was applied for 1 h. Reactivity was detected using diaminobenzidine (DAB, Dako) staining, and the slides were counterstained with Harris-modi®ed hematoxylin (Fisher Scienti®c) according to the manufacturer's instructions. Slides were coverslipped in Permount 1 (Fisher Scienti®c). The following antibodies were used: rabbit anti-phosphoT308Akt1 (Upstate Biotechnology) diluted 1 : 100 and goat anti-cyclin D1 (Santa Cruz) diluted 1 : 200; biotinylated goat anti-rabbit IgG (Kierkegaard and Perry Laboratories) and biotinylated rabbit antigoat IgG (Kirkegaard and Perry Laboratories) diluted 1 : 100.
Western analysis
Total protein was extracted from snap-frozen mammary glands by homogenization using a Dounce homogenizer in 2 ml extraction buer (25 mM Tris pH 7.4, 150 mM NaCl, 0.5 mM sodium vanadate, 50 mM sodium¯uoride, 10 mM sodium pyrophosphate, 1 mM PMSF, 10 mg/ml trypsin inhibitor). Homogenates were centrifuged at 10 000 g for 3 min at 48C, and fat was removed from the surface by vacuum aspiration. The precipitate was resuspended by vortexing, and NP-40 was added to a ®nal concentration of 0.5%. Samples were again homogenized using a Dounce homogenizer and centrifuged. Supernatants were decanted, and protein concentrations determined using the Coomassie protein assay (Pierce). Protein solutions were stored at ± 808C until use.
Approximately 75 mg of protein were diluted in Laemmli sample buer, boiled and loaded onto a 4 ± 20% PAGEr 1 gradient Tris-glycine gel (BioWhittaker). Separated proteins were transferred to Protran nitrocellulose membrane (Schleichler and Schuell). Membranes were blocked with 1% polyvinylpyrrolidone (PVP) in Tris-buered saline-0.1% Tween 20 (TBST) as described by Haycock (1993) . Primary and horseradish-peroxidase (HRP) conjugated secondary antibodies were appropriately diluted in TBST. Bound antibody was detected using SuperSignal West Pico chemiluminescent substrate (Pierce). The following antibodies were used: rabbit antiphospho-T308-Akt1, rabbit anti-phospho-Y705-STAT3, rabbit anti-phospho-S21-GSK3a, and sheep anti-phospho-S136-BAD were from Upstate Biotechnology and diluted 1 : 1000; goat antiactin was from Santa Cruz and diluted 1 : 200. Rabbit anti-goat IgG (Pierce) and goat anti-rabbit IgG (Biorad) were diluted 1 : 15 000. Rabbit anti-sheep IgG (Dako) was diluted 1 : 5000. Figure 8 Expression of phospho-Thr308 AKT1, phospho-Ser136 BAD, phospho-Ser21 GSK-3a and phospho-Tyr705 STAT3 in the mammary gland from wild-type (`WT'), and transgenic mice from founder line 6 (`6'). Western analysis of mammary gland extracts was carried out in the lactating gland at day 0 (d0) and in the involuting gland at day 3 (d3) and day 10 (d10) post-involution. Transgenic and wild-type mice correspond to the respective immunohistochemical data presented in Figures 4, 6 and 7
